S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$70.86
+1.3%
$74.37
$60.01
$85.39
$9.10B0.871.10 million shs768,627 shs
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$24.79
+3.0%
$24.90
$13.34
$28.35
$1.90B0.43642,993 shs319,861 shs
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$26.02
+2.2%
$27.18
$25.00
$34.53
$2.33B1.061.04 million shs533,065 shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$42.37
-2.3%
$48.01
$31.52
$54.98
$3.49B0.65764,819 shs675,380 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Henry Schein, Inc. stock logo
HSIC
Henry Schein
-0.33%-2.56%-5.93%-5.50%-15.65%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
+0.38%-7.25%-4.79%+28.80%+62.68%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
-1.01%-1.01%-5.21%-15.55%-4.61%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-1.65%-14.44%-7.70%-2.74%+3.56%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Henry Schein, Inc. stock logo
HSIC
Henry Schein
4.6497 of 5 stars
3.24.00.03.42.72.52.5
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
3.7592 of 5 stars
2.01.00.03.91.92.53.1
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
4.5807 of 5 stars
3.15.03.31.71.71.71.9
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
4.341 of 5 stars
4.52.00.03.81.92.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.36
Hold$81.0914.44% Upside
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
2.00
Hold$23.29-6.05% Downside
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
2.29
Hold$33.1127.25% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.90
Moderate Buy$91.55116.06% Upside

Current Analyst Ratings

Latest PDCO, OMI, HSIC, and RARE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$48.00
4/10/2024
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $28.00
4/5/2024
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$107.00
3/18/2024
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$88.00 ➝ $92.00
3/6/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$82.00 ➝ $88.00
3/6/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$74.00 ➝ $81.00
3/6/2024
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$31.00 ➝ $30.00
2/29/2024
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$34.00 ➝ $28.00
2/28/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$79.00 ➝ $83.00
2/28/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$82.00 ➝ $90.00
2/27/2024
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$84.00 ➝ $88.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.34B0.74$6.74 per share10.51$33.01 per share2.15
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$10.33B0.18$5.31 per share4.67$12.08 per share2.05
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$6.47B0.36$3.31 per share7.85$11.45 per share2.27
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$434.25M8.03N/AN/A$3.35 per share12.65

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$416M$3.1522.5012.721.743.37%14.03%6.22%5/7/2024 (Confirmed)
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
-$41.30M-$0.54N/A12.650.76-0.40%11.62%2.03%5/3/2024 (Estimated)
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$207.56M$2.0312.8210.491.352.95%20.98%7.70%6/19/2024 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$606.64M-$8.33N/AN/AN/A-139.70%-369.54%-44.74%5/2/2024 (Estimated)

Latest PDCO, OMI, HSIC, and RARE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$0.99N/A-$0.99N/AN/AN/A  
2/28/2024Q3 2024
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$0.60$0.59-$0.01$0.66$1.63 billion$1.62 billion      
2/27/202412/31/2023
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$0.70$0.66-$0.04$1.19$3.00 billion$3.02 billion      
2/20/202412/31/2023
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.66$0.69+$0.03$1.15$2.67 billion$2.66 billion    
2/15/2024Q4 2023
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.65-$1.52+$0.13-$1.52$119.38 million$127.39 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
N/AN/AN/AN/AN/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$1.044.00%N/A51.23%N/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A

Latest PDCO, OMI, HSIC, and RARE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/11/2024
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
Quarterly$0.263.86%4/18/20244/19/20245/3/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.45
1.67
1.00
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
2.05
1.11
0.52
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.46
1.43
0.72
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
2.61
2.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Henry Schein, Inc. stock logo
HSIC
Henry Schein
96.62%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
98.04%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
85.43%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
97.67%

Insider Ownership

CompanyInsider Ownership
Henry Schein, Inc. stock logo
HSIC
Henry Schein
1.14%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
3.59%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.50%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
6.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
25,000128.48 million127.02 millionOptionable
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
13,70076.60 million73.85 millionOptionable
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
7,60089.59 million88.25 millionOptionable
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,27682.30 million76.70 millionOptionable

PDCO, OMI, HSIC, and RARE Headlines

SourceHeadline
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 19 at 4:30 PM
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Raised by Federated Hermes Inc.Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Raised by Federated Hermes Inc.
marketbeat.com - April 18 at 12:23 PM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
markets.businessinsider.com - April 18 at 9:38 AM
Ultragenyx Pharmaceuticals (RARE) "Neutral" Rating Reaffirmed at WedbushUltragenyx Pharmaceutical's (RARE) "Neutral" Rating Reaffirmed at Wedbush
americanbankingnews.com - April 17 at 4:44 AM
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 1.9%Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 1.9%
marketbeat.com - April 16 at 1:40 PM
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease StudyUltragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
zacks.com - April 16 at 12:35 PM
Wedbush Reiterates Neutral Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)Wedbush Reiterates Neutral Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)
marketbeat.com - April 16 at 11:00 AM
Ultragenyx Eyes Pivotal Study After Mid-Stage Win in Angelman SyndromeUltragenyx Eyes Pivotal Study After Mid-Stage Win in Angelman Syndrome
biospace.com - April 16 at 9:55 AM
Mirae Asset Global Investments Co. Ltd. Has $5.18 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Mirae Asset Global Investments Co. Ltd. Has $5.18 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - April 16 at 5:04 AM
Ultragenyx Pharmaceutical (RARE) Set to Announce Earnings on WednesdayUltragenyx Pharmaceutical (RARE) Set to Announce Earnings on Wednesday
americanbankingnews.com - April 16 at 2:52 AM
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Mondays Mid-Day SessionWhy Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
msn.com - April 15 at 6:23 PM
Ultragenyx says Angelman therapy is working, but safety questions remainUltragenyx says Angelman therapy is working, but safety questions remain
biopharmadive.com - April 15 at 1:23 PM
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down to $47.00Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down to $47.00
marketbeat.com - April 15 at 12:53 PM
Ultragenyx Reports Positive Interim Phase 1/2 Data With GTX-102 - Quick FactsUltragenyx Reports Positive Interim Phase 1/2 Data With GTX-102 - Quick Facts
markets.businessinsider.com - April 15 at 8:22 AM
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
finance.yahoo.com - April 15 at 8:22 AM
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman SyndromeUltragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
globenewswire.com - April 12 at 4:22 PM
Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual MeetingUltragenyx Pharmaceutical Inc.: Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
finanznachrichten.de - April 12 at 9:58 AM
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual MeetingUltragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
globenewswire.com - April 12 at 8:00 AM
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Lessened by Peregrine Capital Management LLCUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Lessened by Peregrine Capital Management LLC
marketbeat.com - April 11 at 7:49 AM
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
americanbankingnews.com - April 9 at 4:42 AM
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by AnalystsUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts
marketbeat.com - April 9 at 4:41 AM
Ultragenyx Pharmaceutical, Inc.Ultragenyx Pharmaceutical, Inc.
cnn.com - April 7 at 3:58 AM
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 AnalystsExpert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
markets.businessinsider.com - April 5 at 4:16 PM
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 5.7%Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 5.7%
marketbeat.com - April 5 at 2:38 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Henry Schein logo

Henry Schein

NASDAQ:HSIC
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Owens & Minor logo

Owens & Minor

NYSE:OMI
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment supplies a range of other home medical equipment, patient care products, including ostomy, wound care, urology, incontinence and other products and services. It serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Richmond, Virginia.
Patterson Companies logo

Patterson Companies

NASDAQ:PDCO
Patterson Companies, Inc. engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.
Ultragenyx Pharmaceutical logo

Ultragenyx Pharmaceutical

NASDAQ:RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.